HC Wainwright reissued their buy rating on shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) in a report released on Tuesday, February 6th, MarketBeat Ratings reports. The brokerage currently has a $3.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $5.00.
Separately, ValuEngine upgraded shares of Eyegate Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, February 2nd.
Shares of Eyegate Pharmaceuticals (EYEG) opened at $0.69 on Tuesday. Eyegate Pharmaceuticals has a fifty-two week low of $0.50 and a fifty-two week high of $3.90. The company has a market cap of $11.61, a PE ratio of -0.58 and a beta of 2.91. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 0.01.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last announced its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.24). Eyegate Pharmaceuticals had a negative net margin of 2,480.28% and a negative return on equity of 1,494.75%. equities research analysts anticipate that Eyegate Pharmaceuticals will post -1.01 EPS for the current year.
An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC purchased a new stake in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 345,524 shares of the specialty pharmaceutical company’s stock, valued at approximately $473,000. Sabby Management LLC owned about 2.01% of Eyegate Pharmaceuticals at the end of the most recent reporting period. 11.94% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Eyegate Pharmaceuticals (EYEG) Stock Rating Reaffirmed by HC Wainwright” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/13/eyegate-pharmaceuticals-eyeg-stock-rating-reaffirmed-by-hc-wainwright.html.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.